22157.jpg
Global Cancer Biopsy Market Analysis Report 2021: Advent of Liquid Biopsy & Transition of Novel Oncology Diagnostics from Bench to Clinics - Forecast to 2027
September 20, 2021 04:43 ET | Research and Markets
Dublin, Sept. 20, 2021 (GLOBE NEWSWIRE) -- The "Global Cancer Biopsy Market Size, Share & Trends Analysis Report 2021-2027" report has been added to ResearchAndMarkets.com's offering. The global...
LOGO.jpg
Interpace Biosciences Announces Another Pricing improvement for its Thyroid Assay
February 11, 2020 06:55 ET | Interpace Biosciences, Inc.
Parsippany, NJ, Feb. 11, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (Nasdaq: IDXG) today announced that the Center for Medicare and Medicaid Services (CMS) has modified the reimbursement...
LOGO.jpg
Interpace Biosciences Announces New Draft LCD and Reimbursement for Its Proprietary Thyroid Assay, ThyGeNEXT®
December 17, 2019 06:55 ET | Interpace Biosciences, Inc.
Parsippany, NJ, Dec. 17, 2019 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (Nasdaq: IDXG) today announced that its Medicare Administrative Contractor (MAC) has issued a new draft local coverage...
Logo.png
Interpace Diagnostics Enters Agreement with Predictive Oncology to Enhance Diagnosis of Thyroid Cancer Via AI-Driven Analysis
July 18, 2019 06:55 ET | Interpace Diagnostics Group, Inc.
PARSIPPANY, NJ, July 18, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) (“Interpace” or the “Company), announced today that it has executed an agreement with the Helomics...
ThyCaLogo_wttxt reverse 2015.jpg
International Thyroid Cancer Survivors' Conference Brings Together Survivors, Caregivers, and Expert Speakers in Chicago, October 19-21
October 02, 2018 10:01 ET | ThyCa
CHICAGO, Oct. 02, 2018 (GLOBE NEWSWIRE) -- ThyCa: Thyroid Cancer Survivors' Association, Inc., has secured an impressive lineup of more than 35 expert speakers for the 21st International Thyroid...
Interpace Diagnostics Announces CIGNA’s Expansion of Coverage to Now Include ThyraMIR®
July 26, 2018 08:37 ET | Interpace Diagnostics Group, Inc.
PARSIPPANY, N.J., July 26, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (IDXG) (“Interpace” or “the Company”), a fully integrated commercial and bioinformatics company that provides...
Interpace Diagnostics Group Reports First Quarter 2018 Financial Results, Business Progress and Recent Accomplishments
May 15, 2018 08:00 ET | Interpace Diagnostics Group, Inc.
Revenue Grew 39% Over the Prior Year’s Quarter and 10% Over the Prior Period Record Quarterly Revenue of $4.8 Million and Record Quarterly Cash Receipts of $4.4 Million Cash & Cash Equivalents...
Interpace Diagnostics Announces Launch of New Thyroid Test
May 14, 2018 08:30 ET | Interpace Diagnostics Group, Inc.
BOSTON, May 14, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) (“Interpace” or “the Company”), a fully integrated commercial and bioinformatics company that provides...
Interpace Diagnostics to Host Conference Call and Webcast to Discuss First Quarter 2018 Financial Results, Business Progress and Recent Accomplishments on Tuesday, May 15, 2018
May 11, 2018 09:10 ET | Interpace Diagnostics Group, Inc.
PARSIPPANY, N.J., May 11, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) (“Interpace” or “the Company”), a fully integrated commercial and bioinformatics company that...
Interpace Diagnostics Announces Expanded Coverage Among Blue Cross Blue Shield Plans
May 10, 2018 09:00 ET | Interpace Diagnostics Group, Inc.
PARSIPPANY, N.J., May 10, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) (“Interpace” or “the Company”), a fully integrated commercial and bioinformatics company that...